Cargando…
Characteristics of anti-IL-17/23 biologics-induced interstitial pneumonia in patients with psoriasis
OBJECTIVES: Anti-IL-17/23 biologics are increasingly used to treat psoriasis. We aimed to elucidate characteristics of drug-induced interstitial pneumonia (DIIP) caused by anti-IL-17/23 biologics. METHODS: We retrospectively analyzed the clinical data of psoriasis patients treated with anti-IL-17/23...
Autores principales: | Miyagawa, Hanae, Hara, Hiromichi, Araya, Jun, Minagawa, Shunsuke, Numata, Takanori, Umezawa, Yoshinori, Asahina, Akihiko, Nakagawa, Hidemi, Kuwano, Kazuyoshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7790374/ https://www.ncbi.nlm.nih.gov/pubmed/33411857 http://dx.doi.org/10.1371/journal.pone.0245284 |
Ejemplares similares
-
Interstitial Pneumonia in Psoriasis
por: Kawamoto, Hironori, et al.
Publicado: (2018) -
Long-Term Efficacy and Clinical Remission After Benralizumab Treatment in Patients with Severe Eosinophilic Asthma: A Retrospective Study
por: Numata, Takanori, et al.
Publicado: (2022) -
Real-World Effectiveness of Dupilumab for Patients with Severe Asthma: A Retrospective Study
por: Numata, Takanori, et al.
Publicado: (2022) -
Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study
por: Numata, Takanori, et al.
Publicado: (2020) -
Effectiveness of Switching Biologics for Severe Asthma Patients in Japan: A Single-Center Retrospective Study
por: Numata, Takanori, et al.
Publicado: (2021)